Academic Journal
Q1npj Parkinson s Disease
About npj Parkinson s Disease
About npj Parkinson s Disease
npj Parkinson s Disease is a peer-reviewed scholarly journal published by Nature Portfolio.
Key indicators: ISSN 23738057.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
Publishing in npj Parkinson s Disease
When considering this journal, verify its current indexing status, editorial board, and recent publications to ensure it meets your needs for visibility and credibility.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of npj Parkinson s Disease?
23738057.
Who publishes npj Parkinson s Disease?
Nature Portfolio.
Where do I submit to npj Parkinson s Disease?
Via the official website.
Is npj Parkinson s Disease peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Journal Metrics
A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
A ‘brain-first’ mouse model of progressive alpha-synuclein pathology via intranasal rotenone administration
Monika Sharma, Nishant Sharma, Jhanvi Soni, Manasi Uttarkar et al.
2026-10-08 · DOI: 10.1038/s41531-026-01593-4Multi-omics of host–gut metabolic crosstalk in Parkinson’s disease
Tzi Shin Toh, Chun Wie Chong, Mun Fai Loke, Lei Cheng Lit et al.
2026-10-05 · DOI: 10.1038/s41531-026-01561-yInterpretable survival prediction in Parkinson’s disease with AI-assisted web deployment
Tingwei Song, Yuan Liu, Linghui Xiang, Hongxu Pan et al.
2026-10-03 · DOI: 10.1038/s41531-026-01589-0Alterations of subcortical structures are associated with anxiety in early Parkinson’s disease patients: a cross-sectional 7T MRI study
Guillaume Carey, Michiel van Lier, Stijn Michielse, Amée F. Wolters et al.
2026-10-03 · DOI: 10.1038/s41531-026-01532-3The impact of nocturnal hypokinesia on supervised and unsupervised mobility in people with Parkinson’s disease
Edoardo Bianchini, Pietro Lombardo, Tracy Milane, Domiziana Rinaldi et al.
2026-10-03 · DOI: 10.1038/s41531-026-01587-2Identification of novel autoantibodies in Parkinson’s disease using a functional protein array platform
Yin Xia Chao, Bernett TK Lee, Suh Yee Goh, Muhammad Yaaseen Gulam et al.
2026-10-02 · DOI: 10.1038/s41531-026-01568-5Resting state fMRI network topographies in preclinical and early Parkinson’s disease stages
Amgad Droby, Nha Nguyen, Patrick Do, Jack Truong et al.
2026-10-01 · DOI: 10.1038/s41531-026-01584-5Prodromal non-motor symptom trajectories preceding Parkinson disease diagnosis: a retrospective matched case-control study using the All of Us Research Program
Meet Popatbhai Kachhadia, Sameea Husain Wilson, Marc A. Swerdloff, Juber D. Shaikh et al.
2026-09-30 · DOI: 10.1038/s41531-026-01591-6Cognitive impairment in Parkinson’s disease: prevalence and associations with cardiometabolic, vascular, and autonomic factors—a systematic review and meta-analysis
Jiang Wang, Hongshuai Zhou, Tian Tian, Jiayuan Wen et al.
2026-09-28 · DOI: 10.1038/s41531-026-01573-8Hypokinesia and bradykinesia in Parkinson’s disease are consistent with reduced motor vigour, not an impaired capacity to generate and transmit neural drive to muscle
Vishal Rawji, Cosima Graef, Thomas Foltynie, Shlomi Haar et al.
2026-09-28 · DOI: 10.1038/s41531-026-01590-7Functional pathway phenotyping reveals increased LRRK2 activity beyond recognised genetic causes of Parkinson’s disease
Neringa Pratuseviciute, Walter Pirker, Jennifer Huber, Sara Gomes et al.
2026-09-26 · DOI: 10.1038/s41531-026-01575-6Two-year smartphone motor monitoring in isolated REM sleep behavior disorder and Parkinson’s disease
Vojtěch Illner, Michal Novotný, Tomáš Kouba, Tereza Tykalová et al.
2026-09-26 · DOI: 10.1038/s41531-026-01588-1Reply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease
Guillaume Cogan, Christelle Tesson, Lisa Welment, Fabienne Clot et al.
2026-09-25 · DOI: 10.1038/s41531-026-01470-0Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease
Christian A. Ganoza, Ana Westenberger, Jefri J. Paul, Filipa Curado et al.
2026-09-25 · DOI: 10.1038/s41531-026-01562-xStem cell-derived brain repair for Parkinson’s disease: a review of strategies to improve engraftment
Giulia Comini, Mark Denham, Eilís Dowd
2026-09-25 · DOI: 10.1038/s41531-026-01574-7Effects of thioredoxin-1 on oligodendrocyte lineage cells altered by the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Fang Yan, Qimeng Xia, Xiaowei Sun, Jiaoyang Duan et al.
2026-09-24 · DOI: 10.1038/s41531-026-01581-8Unified long-read panel for Parkinson’s and repeat expansion disorders
André Fienemann, Julia C. Prietzsche, Joshua Laβ, Christoph Much et al.
2026-09-24 · DOI: 10.1038/s41531-026-01585-4Interaction- and asymmetry-aware facial blendshape analysis for objective quantification of Parkinsonian hypomimia
Berkan Koyak, Timo Menzel, Martin Rodemann, Guido Hennes et al.
2026-09-23 · DOI: 10.1038/s41531-026-01579-2Time-to-event analyses of motor examination and functional outcomes in early Parkinson’s disease clinical trials
Andrew McGarry, Christopher R. Meyer, Karl Kieburtz, Jordan Dubow et al.
2026-09-23 · DOI: 10.1038/s41531-026-01578-3Epigenome-wide meta-analysis of sex-differential DNA methylation in Parkinson’s disease
Tianmi Yang, Chunyu Li, Qianqian Wei, Dejiang Pang et al.
2026-09-23 · DOI: 10.1038/s41531-026-01582-7Reviews
Community Reviews
Version History
October 11, 2026 at 2:55 am
October 9, 2026